PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|June 8, 2015
Top Five Pharma CEO Paypackets Total More Than $100M
Author(s)News Update
June 8, 2015.
Advertisement
Looking at aggregated data from The New York Times, which used filings from the Securities and Exchange Commission to compute CEO compensation,
Motley Fool lists the five best-paid pharma CEOs as
- Lamverto Andriotti, BMS: $26.1 million
- Kenneth Frazier, Merck: $21.4 million
- Alex Gorksy, J&J: 20.4 million
- Ian Read, Pfizer: $18 million
- Richard Gonzalez, AbbVie: $17 million.
The key question, the reports asks, is "
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
3
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5